PFE
Pfizer Inc.
Stock
$28.72+0.05 (+0.17%)Close Sep 28, 2026
Cash flow statement
| Line | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $13.4B | $11.7B | $12.7B | $8.7B | $29.3B | $32.6B | $14.4B | $12.6B | $15.8B | $16.8B | $16.2B | $14.7B | $17.1B | $17.7B | $16.7B | $20.2B | $11.5B | $16.6B | $18.2B | $13.4B |
| Capital expenditures | $2.4B | $2.6B | $2.9B | $3.9B | $3.2B | $2.7B | $2.2B | $2.0B | $2.0B | $2.0B | $1.8B | $1.4B | $1.2B | $1.2B | $1.3B | $1.7B | $1.5B | $1.2B | $1.7B | $1.9B |
| Free cash flow | $11.0B | $9.1B | $9.8B | $4.8B | $26.0B | $29.9B | $12.2B | $10.5B | $13.8B | $14.8B | $14.4B | $13.3B | $15.9B | $16.5B | $15.4B | $18.6B | $9.9B | $15.4B | $16.5B | $11.5B |
| Stock-based compensation | $947M | $799M | $877M | $525M | $872M | $1.2B | $755M | $687M | $923M | $840M | $691M | $669M | $586M | $523M | $481M | $419M | $405M | $349M | $384M | $437M |
| Buybacks | — | — | $0 | $0 | $2.0B | $0 | $0 | $8.9B | $12.2B | $5.0B | $5.0B | $6.2B | $5.0B | $16.3B | $8.2B | $9.0B | $1.0B | $0 | $500M | $10.0B |
| Dividends per share | $1.72 | $1.72 | $1.69 | $1.65 | $1.61 | $1.57 | $1.53 | $1.46 | $1.38 | $1.30 | $1.22 | $1.12 | $1.04 | $0.96 | $0.88 | $0.80 | $0.72 | — | — | — |
| Free cash flow margin | 17.2% | 14.5% | 15.5% | 8.0% | 25.7% | 36.7% | 29.2% | 25.8% | 33.9% | 28.3% | 27.2% | — | — | 31.9% | 28.2% | 30.4% | 15.3% | 31.2% | 34.2% | 23.7% |